![]() This represents a change of +168.4% from what the company reported a year ago. MGNX has returned -2.5% over the past month.For MacroGenics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.65. One other stock in the same industry, MacroGenics MGNX, finished the last trading session 1.4% higher at $5.87. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >SurModics is a member of the Zacks Medical - Products industry. So, make sure to keep an eye on SRDX going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. Revenues are expected to be $24.19 million, up 5.2% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For SurModics, the consensus EPS estimate for the quarter has been revised 3.5% lower over the last 30 days to the current level. Also, Surmodics’ announcement of favorable data regarding the differentiated capabilities of its crystalline drug release platform for sirolimus-coated balloons in connection with 12-month data from its SWING trial at the recently-concluded International Symposium on Endovascular Therapy raises optimism.This drug delivery technology company is expected to post quarterly loss of $0.65 per share in its upcoming report, which represents a year-over-year change of -400%. The company is expected to release its fiscal first-quarter earnings on Feb 2, 2023. ![]() This compares to the stock's 22.4% loss over the past four weeks.Surmodics recorded a strong price increase before its first-quarter fiscal 2023 earnings release with the latest Zacks Consensus Estimate showing significant upward revision for its quarterly revenues compared to the year-ago reported number. The move was backed by solid volume with far more shares changing hands than in a normal session. Sidoti promotes meaningful interaction between issuers and investors in the Small Cap and Micro-Cap space through a series of investor conferences ( we host each year.SurModics SRDX shares soared 6.1% in the last trading session to close at $27. and Canada, including many leading institutional managers. We serve 500+ institutional clients in the U.S. Our approach affords companies and institutional clients a combination of high-quality research, a Small Cap and Micro-Cap focused nationwide sales effort, and broad access to corporate management teams. ![]() Virtual Agenda - Thursday, March 23rd - All Times EDTįor over two decades, Sidoti has been a premier provider of independent securities research focused specifically on Small Cap and Micro-Cap companies and the institutions that invest their securities, with most of our coverage in the $50 million to $3 billion market cap range. Silvercrest Asset Management Group (SAMG) Click on Company Name to Open Link to Zoom Meeting ![]()
0 Comments
Leave a Reply. |